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BACKGROUND
Hereditary transthyretin amyloidosis is caused by pathogenic single-nucleotide variants 
in the gene encoding transthyretin (TTR) that induce transthyretin misfolding and 
systemic deposition of amyloid. Progressive amyloid accumulation leads to multi-
organ dysfunction and death. Inotersen, a 2′-O-methoxyethyl–modified antisense 
oligonucleotide, inhibits hepatic production of transthyretin.
METHODS
We conducted an international, randomized, double-blind, placebo-controlled, 15-month, 
phase 3 trial of inotersen in adults with stage 1 (patient is ambulatory) or stage 2 
(patient is ambulatory with assistance) hereditary transthyretin amyloidosis with poly-
neuropathy. Patients were randomly assigned, in a 2:1 ratio, to receive weekly sub-
cutaneous injections of inotersen (300 mg) or placebo. The primary end points were 
the change in the modified Neuropathy Impairment Score+7 (mNIS+7; range, −22.3 
to 346.3, with higher scores indicating poorer function; minimal clinically meaningful 
change, 2 points) and the change in the score on the patient-reported Norfolk Quality 
of Life–Diabetic Neuropathy (QOL-DN) questionnaire (range, −4 to 136, with higher 
scores indicating poorer quality of life). A decrease in scores indicated improvement.
RESULTS
A total of 172 patients (112 in the inotersen group and 60 in the placebo group) re-
ceived at least one dose of a trial regimen, and 139 (81%) completed the intervention 
period. Both primary efficacy assessments favored inotersen: the difference in the 
least-squares mean change from baseline to week 66 between the two groups (inot-
ersen minus placebo) was −19.7 points (95% confidence interval [CI], −26.4 to −13.0; 
P<0.001) for the mNIS+7 and −11.7 points (95% CI, −18.3 to −5.1; P<0.001) for the 
Norfolk QOL-DN score. These improvements were independent of disease stage, 
mutation type, or the presence of cardiomyopathy. There were five deaths in the 
inotersen group and none in the placebo group. The most frequent serious adverse 
events in the inotersen group were glomerulonephritis (in 3 patients [3%]) and throm-
bocytopenia (in 3 patients [3%]), with one death associated with one of the cases of 
grade 4 thrombocytopenia. Thereafter, all patients received enhanced monitoring.
CONCLUSIONS
Inotersen improved the course of neurologic disease and quality of life in patients 
with hereditary transthyretin amyloidosis. Thrombocytopenia and glomerulonephri-
tis were managed with enhanced monitoring. (Funded by Ionis Pharmaceuticals; 
NEURO-TTR ClinicalTrials.gov number, NCT01737398.)
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A utosomal dominant mutations in the gene encoding transthyretin (TTR) cause a rare systemic disorder known as 
hereditary transthyretin amyloidosis. The single 
amino-acid changes that result from these muta-
tions destabilize the tetrameric transthyretin pro-
tein complex to cause aggregation of monomers 
into insoluble, extracellular amyloid deposits.1 Ac-
cumulation of amyloid deposits in multiple organ 
systems leads to progressive peripheral polyneu-
ropathy, cardiomyopathy, nephropathy, and gastro-
intestinal dysfunction.2-5 The average life expec-
tancy, untreated, from symptom onset is 3 to 15 
years.6 The presence of cardiomyopathy is asso-
ciated with a worse prognosis. Patients typically 
die from malnutrition and cachexia, renal failure, 
cardiac disease, and sudden death.7
The liver is the primary source of systemic 
transthyretin protein. Liver transplantation has 
historically been the standard of care for heredi-
tary transthyretin amyloidosis, but continued de-
position of wild-type transthyretin amyloid after 
transplantation can limit its effectiveness.8-11 Al-
though some treatments are currently available 
— such as tafamidis (Vyndaqel) and diflunisal, 
small molecules that stabilize the circulating tetra-
meric form of transthyretin and slow disease pro-
gression11-16 — additional treatments could be of 
value.
Inotersen (formerly IONIS-TTRRx/ISIS 420915) 
is a 2′-O-methoxyethyl–modified antisense oligo-
nucleotide inhibitor of the hepatic production of 
transthyretin protein. In healthy volunteers, inot-
ersen showed dose-dependent and sustained re-
ductions of circulating transthyretin levels.17 We 
conducted a randomized, double-blind, placebo-
controlled, phase 3 trial (NEURO-TTR) to deter-
mine the efficacy and safety of inotersen treatment 
in patients with hereditary transthyretin amyloi-




The trial was conducted at 24 centers in 10 coun-
tries. Adults 18 to 82 years of age who had received 
a diagnosis of stage 1 (patient is ambulatory) or 
stage 2 (patient is ambulatory with assistance) he-
reditary transthyretin amyloidosis with polyneu-
ropathy and who had a Neuropathy Impairment 
Score (NIS) of 10 to 130, a TTR mutation deter-
mined by genotyping, and documented amyloid 
deposits determined on biopsy were eligible for 
this trial. The NIS scale ranges from 0 to 244 
points, with a higher score indicating poorer func-
tion and a minimal clinically meaningful differ-
ence of 2 points.18 Key exclusion criteria were 
clinically significant abnormalities in screening 
laboratory values, a Karnofsky performance status 
score of 50 or less (on a scale of 0 to 100, with 
lower scores indicating greater disability), other 
causes of polyneuropathy besides hereditary trans-
thyretin amyloidosis, previous liver transplanta-
tion, and heart failure of New York Heart Asso-
ciation class III or higher. The use of tafamidis 
or diflunisal during the intervention period was 
not allowed.
Trial Oversight
The trial protocol, available with the full text of 
this article at NEJM.org, was approved by insti-
tutional review boards or local ethics commit-
tees. The trial was conducted in accordance with 
Good Clinical Practice guidelines of the Interna-
tional Conference on Harmonisation and the 
principles of the Declaration of Helsinki. All the 
patients provided written informed consent to 
participate in the trial. An independent data and 
safety monitoring committee reviewed unblind-
ed safety data approximately four times per year.
Data were collected by the site investigators, 
and the sponsor (Ionis Pharmaceuticals) was re-
sponsible for data analysis. All the authors had full 
access to the data. The first draft of the manu-
script was written by a contract medical writer 
and the sponsor, with input from the authors on 
subsequent drafts. All the authors approved the 
final version, made the decision to submit the 
manuscript for publication, vouch for the com-
pleteness and accuracy of the data and analyses 
presented, and affirm that the trial was conduct-
ed and reported with fidelity to the protocol and 
statistical analysis plan, available with the pro-
tocol at NEJM.org.
Trial Design
After a 6-week screening period, eligible patients 
were randomly assigned, in a 2:1 ratio, to receive 
300 mg of inotersen (equivalent to 284 mg of free 
acid) or placebo (Fig. S1 in the Supplementary Ap-
pendix, available at NEJM.org). Patients were strat-
ified according to the following factors: Val30Met 
TTR mutation (148G→A) versus non-Val30Met TTR 
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mutation, stage 1 versus stage 2 disease, and previ-
ous treatment with tafamidis or diflunisal versus 
no known previous treatment. Patients received 
three subcutaneous injections during the first 
week to achieve near steady-state drug levels, fol-
lowed by a once-weekly subcutaneous injection 
for the next 64 weeks. A total of 13 of 67 doses 
(19%) were required to be administered at pre-
specified clinical visits. All other doses could be 
administered at home by the patient, a trained 
family member, or a health professional. All the 
patients received vitamin A supplements at the 
recommended daily allowance (approximately 
3000 IU) to ensure adequate delivery of dietary 
vitamin A to tissues in the context of low trans-
thyretin levels. The trial also included a 1-week 
efficacy-assessment period and a 6-month post-
intervention evaluation period if a patient was 
not enrolled in the open-label extension study.
End Points and Assessments
The primary end points were the change from 
baseline to week 66 in the standardized modi-
fied Neuropathy Impairment Score+7 (mNIS+7) 
composite score18-22 and in the total score on the 
Norfolk Quality of Life–Diabetic Neuropathy 
(QOL-DN) questionnaire.23,24 The mNIS+7 has 
eight components, with a composite score rang-
ing from −22.3 to 346.3 (the higher the score, 
the poorer the function). A decrease in score in-
dicates an improvement, and a 2-point change 
has been defined as the minimal clinically mean-
ingful change detectable.14,18 The Norfolk QOL-DN 
is a 35-item questionnaire that comprises five 
domains, with a total score ranging from −4 to 
136 (the higher the score, the poorer the quality 
of life). Changes in the patient-reported Norfolk 
QOL-DN score have been shown to be propor-
tional to changes in the NIS.24 (See Table S1 in 
the Supplementary Appendix for complete scor-
ing scales according to component of the mNIS+7 
and domain of the Norfolk QOL-DN question-
naire.) All mNIS+7 assessors were specially trained 
and prequalified by a central reader. The NIS 
component was performed by an independent 
neurologist who was not aware of the trial-group 
assignments and not involved in the day-to-day 
conduct of the trial or care of the patient. Safety 
assessments included collection of adverse events 
that occurred from the time of the first dose to 
the end of the trial (including the postinterven-
tion follow-up period), clinical laboratory tests, 
vital signs, 12-lead electrocardiography, and elec-
troretinography (ERG) examinations to detect early 
signs of vitamin A deficiency.
Statistical Analysis
The planned sample of 135 patients was calcu-
lated under the assumptions of an effect size of 
9.6 points and a standard deviation of 14 in the 
mNIS+7, an effect size of 10.7 and a standard de-
viation of 18 in the Norfolk QOL-DN score, and 
a dropout rate of 25%. Using a 2:1 allocation ra-
tio, we estimated that the trial had a power of at 
least 90% for the mNIS+7 end point and a power 
of at least 80% for the Norfolk QOL-DN end point, 
using a two-sided test with an alpha level of 5%.
Efficacy analyses included all randomly as-
signed patients who received at least one dose of 
a trial regimen and who had at least one post-
baseline efficacy assessment for the mNIS+7 or 
the Norfolk QOL-DN score. Subgroup analyses 
were performed on the basis of the three strati-
fication factors and according to the presence or 
absence of cardiomyopathy, geographic region, 
and selected demographic characteristics for each 
of the two end points. The presence of cardio-
myopathy was defined by a diagnosis of trans-
thyretin cardiomyopathy at trial entry or by the 
following criteria: an interventricular wall thick-
ness of 13 mm or more on transthoracic echocar-
diography at baseline, as ascertained by a central 
reader, and no known history of persistent hyper-
tension (systolic blood pressure, ≥150 mm Hg) 
within 12 months before screening. Safety analy-
ses were performed on all randomly assigned 
patients who received at least one dose of a trial 
regimen.
The primary end points were analyzed with 
the use of a ranking strategy, with the mNIS+7 
tested first and the Norfolk QOL-DN score tested 
second. No adjustments were made for multiple 
testing. The data were analyzed with the use of a 
mixed-effects model with repeated measures. The 
mNIS+7 was scored at baseline (two assessments), 
week 35 (one assessment), and week 66 (two as-
sessments). The two assessments at baseline and 
week 66 were averaged at the component level. 
Week 66 was the time point for the primary 
analysis. Predefined sensitivity analyses included 
alternative methods for imputing missing data 
at the visit level. A total of 16 prespecified sub-
group analyses are reported. Data are summarized 
according to trial group with the use of descrip-
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tive summary statistics. All statistical tests were 
conducted with the use of two-sided tests with an 
alpha level of 5%. Additional details on eligibility 
criteria, trial regimens, efficacy and safety assess-
ments, and methods of statistical analysis are 
provided in the Supplementary Appendix.
R esult s
Patient Characteristics and Follow-up
The trial was conducted from March 2013 through 
November 2017. Of 278 patients who were 
screened for participation in the trial, 173 were 
randomly assigned in a 2:1 ratio to receive inot-
ersen or placebo (Fig. 1). A total of 172 patients 
(112 in the inotersen group and 60 in the pla-
cebo group) received at least one dose of a trial 
regimen. The baseline characteristics were well 
balanced overall between the two groups (Ta-
ble 1). The mean age of the trial population was 
59 years; 69% of the patients were male, and 92% 
of the patients were white. Approximately half 
carried the Val30Met mutation (from a total of 
27 mutations). A total of 67% of the patients had 
stage 1 disease, 58% had previously received ta-
famidis or diflunisal, and 63% had cardiomyopa-
thy. At the time of trial entry, cardiomyopathy was 
more prevalent in the inotersen group than in 
the placebo group, and patients in the inotersen 
group had a longer duration of disease (since diag-
nosis of cardiomyopathy) than those in the placebo 
group.
Of the 172 randomly assigned patients who 
received at least one dose of a trial regimen, 139 
(81%) completed the 15-month intervention pe-
riod (Fig. 1). A total of 25 (22%) of the patients 
who received inotersen and 8 (13%) of those who 
received placebo discontinued the trial regimen. 
Adverse events were the main reason for discon-
tinuation in the inotersen group (16 patients, 14%), 
whereas voluntary withdrawal (3 patients, 5%) 
and disease progression (3 patients, 5%) were the 
most common reasons for discontinuation in the 
placebo group. A total of 135 patients were en-
rolled in the open-label extension study.
Primary Efficacy End Points
Both primary end points, the mNIS+7 and the 
Norfolk QOL-DN score, achieved significant dif-
ferences between the inotersen group and the 
placebo group at week 66 after 15 months of inter-
vention (Fig. 2). The difference in least-squares 
mean change from baseline to week 66 between 
the two groups (inotersen minus placebo) was 
−19.7 points (95% confidence interval [CI], −26.4 
to −13.0; P<0.001) for the mNIS+7 and −11.7 
points (95% CI, −18.3 to −5.1; P<0.001) for the 
Norfolk QOL-DN score, favoring inotersen (Ta-
ble S3 in the Supplementary Appendix). Moreover, 
significant between-group differences were ob-
served in both end points at the interim week 35 
assessment. At week 35, the difference in the 
least-squares mean change from baseline for the 
mNIS+7 was −8.7 points (95% CI, −13.5 to −3.9; 
P<0.001) and for the Norfolk QOL-DN score was 
−6.1 points (95% CI, −11.8 to −0.5; P = 0.03). 
Prespecified sensitivity analyses showed a robust 
and beneficial inotersen treatment effect under 
all assumptions (Table S4 in the Supplementary 
Appendix).
On average, patients who received inotersen 
had an increase of 5.8 points (95% CI, 1.6 to 10.0) 
from baseline in the mNIS+7 (vs. 25.5 points 
[95% CI, 20.2 to 30.8] with placebo) and of 1.0 
points (95% CI, −3.2 to 5.2) in the Norfolk QOL-
DN score (vs. 12.7 points [95% CI, 7.4 to 17.9] 
with placebo) by the end of the intervention pe-
riod. Further analysis of patients who completed 
the intervention period showed that 36% of the 
patients in the inotersen group had an improve-
ment (no increase from baseline) in the mNIS+7 
and 50% had an improvement in the Norfolk 
QOL-DN score (Table S5 in the Supplementary 
Appendix).
All subgroup analyses that were performed 
according to stratification factor showed a signifi-
cant benefit of inotersen as compared with placebo 
at week 66 in the mNIS+7 (difference in least-
squares mean change from baseline: Val30Met 
mutation, −18.9 [95% CI, −28.1 to −9.6; P<0.001], 
and non-Val30Met mutation, −21.3 [95% CI, −31.1 
to −11.5; P<0.001]; stage 1 disease, −14.2 [95% CI, 
−22.5 to −5.9; P<0.001], and stage 2 disease, −29.1 
[95% CI, −40.2 to −18.0; P<0.001]; previous treat-
ment with tafamidis or diflunisal, −20.0 [95% CI, 
−29.2 to −10.8; P<0.001], and no previous treat-
ment, −20.8 [95% CI, −30.6 to −11.0; P<0.001]), 
consistent with the results of the primary analy-
sis. The benefit of inotersen over placebo for the 
subgroup analyses according to the Norfolk 
QOL-DN stratification factor was also consistent 
with the primary analysis (difference in least-
squares mean change from baseline: Val30Met 
mutation, −12.2 [95% CI, −21.6 to −3.0; P = 0.01], 
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and non-Val30Met mutation, −11.1 [95% CI, −20.9 
to −1.4; P = 0.03]; stage 1 disease, −9.9 [95% CI, 
−18.2 to −1.7; P = 0.02], and stage 2 disease, −15.0 
[95% CI, −26.2 to −3.9; P = 0.008]; previous treat-
ment with tafamidis or diflunisal, −9.0 [95% CI, 
−18.2 to 0.1; P = 0.05], and no previous treatment, 
−14.7 [95% CI, −24.5 to −4.9; P = 0.003]). (For de-
tails, see Figs. S2 and S3 in the Supplementary 
Appendix.)
Consistent benefit for both primary end 
points in favor of inotersen was also observed at 
week 66 when analyzed according to the presence 
of cardiomyopathy (difference in least-squares 
mean change from baseline: mNIS+7, −17.2 
[95% CI, −25.6 to −8.7; P<0.001]; Norfolk QOL-DN 
score, −9.0 [95% CI, −17.5 to −0.6; P = 0.04]) or 
absence of cardiomyopathy (difference in least-
squares mean change from baseline: mNIS+7, 
Figure 1. Randomization and Follow-up.
One patient in the inotersen group underwent randomization in error and did not begin the trial regimen. Adverse 
events leading to discontinuation of inotersen were thrombocytopenia (in 2 patients), abdominal distention, intesti-
nal perforation, nausea, vomiting, pyrexia, hypersensitivity, decreased platelet count, cachexia (in 2 patients), arthralgia, 
myalgia, chorea, dementia, embolic stroke, intracranial hemorrhage, myelopathy, myoclonus, acute kidney injury, 
glomerulonephritis, tubulointerstitial nephritis, pruritus, reticular erythematous mucinosis, and deep-vein thrombo-
sis; 6 of 16 patients (38%) discontinued inotersen because of multiple events. Adverse events leading to discontinu-
ation of placebo were pain, increased weight, and arthralgia. Of the 2 patients in the inotersen group who discontin-
ued the trial regimen because they were withdrawn by the sponsor, 1 patient whose data were unblinded for safety 
monitoring was allowed to enroll in the open-label extension study. NIS denotes Neuropathy Impairment Score.
173 Underwent randomization (2:1 ratio)
278 Patients were assessed for eligibility
105 Were excluded
97 Did not meet eligibility criteria
49 Had NIS that was out of range
4 Withdrew consent
4 Had other reasons
1 Was ineligible
112 Were assigned to receive
inotersen, 300 mg
60 Were assigned to receive
placebo
25 Discontinued trial regimen
16 Had adverse event
2 Had disease progression




1 Underwent liver trans-
plantation
8 Discontinued trial regimen
3 Withdrew voluntarily
3 Had disease progression
1 Had adverse event
1 Met renal stopping rule
87 Completed the trial 52 Completed the trial
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Age — yr 59.5±14.0 59.0±12.5 59.2±13.0
Male sex — no. (%) 41 (68) 77 (69) 118 (69)
Race — no. (%)†
White 53 (88) 105 (94) 158 (92)
Black 1 (2) 3 (3) 4 (2)
Asian 3 (5) 1 (<1) 4 (2)
Other or multiple 3 (5) 3 (3) 6 (3)
Geographic region — no. (%)
Europe 23 (38) 37 (33) 60 (35)
North America 26 (43) 56 (50) 82 (48)
South America or Australasia 11 (18) 19 (17) 30 (17)
BMI‡ 24.2±4.9 24.0±4.9 24.1±4.9
Modified BMI§ 105.0±22.8 101.1±22.8 102.5±22.8
Val30Met TTR mutation — no. (%)¶‖ 33 (55) 56 (50) 89 (52)
Disease stage — no. (%)‖**
1: patient is ambulatory 42 (70) 74 (66) 116 (67)
2: patient is ambulatory with assistance 18 (30) 38 (34) 56 (33)
Previous treatment with tafamidis or diflunisal — no. (%)‖ 36 (60) 63 (56) 99 (58)
Duration of disease from diagnosis of hATTR-PN — mo†† 39.3±40.3 42.4±51.2 41.3±47.6
Stage 1 45.4±43.1 43.2±47.8 44.0±46.0
Stage 2 24.8±29.0 40.9±57.8 35.8±50.7
Duration of disease from onset of hATTR-PN symptoms 
— mo††
64.0±52.3 63.9±53.2 63.9±52.7
Stage 1 64.4±53.0 59.4±53.1 61.2±52.9
Stage 2 63.2±52.2 72.6±52.9 69.6±52.4
Presence of cardiomyopathy — no. (%)‡‡ 33 (55) 75 (67) 108 (63)
mNIS+7 composite score§§ 74.8±39.0 79.2±37.0 77.6±37.6
Norfolk QOL-DN total score¶¶ 48.7±26.7 48.2±27.5 48.4±27.2
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. The term hATTR-PN denotes 
hereditary transthyretin amyloidosis with polyneuropathy.
†  Race was reported by the patients.
‡  The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.
§  The modified BMI was defined as BMI × albumin level in grams per deciliter.
¶  See Table S2 in the Supplementary Appendix for a complete listing of TTR mutations represented in the trial.
‖  Values are based on data from the electronic case-report form.
**  Baseline disease stage and polyneuropathy disability scores were compared and queried as necessary for consistency 
at the center level in the assessment of ambulatory status.
††  Only year and month were collected for diagnosis of hATTR-PN and onset of hATTR-PN symptoms. The duration 
from diagnosis of hATTR-PN and onset of hATTR-PN symptoms was calculated relative to the date of informed con-
sent.
‡‡  The presence of cardiomyopathy was defined by a diagnosis of transthyretin cardiomyopathy at trial entry or by the 
following criteria: an interventricular wall thickness of 13 mm or more on transthoracic echocardiography at baseline, 
as ascertained by a central reader, or no known history of persistent hypertension (systolic blood pressure, ≥150 mm 
Hg) within 12 months before screening.
§§  Composite scores on the modified Neuropathy Impairment Score+7 (mNIS+7) scale range from −22.3 to 346.3, with 
higher scores indicating poorer function.
¶¶  Total scores on the Norfolk Quality of Life–Diabetic Neuropathy (QOL-DN) questionnaire range from −4 to 136, with 
higher score indicating poorer quality of life.
Table 1. Baseline Demographic and Clinical Characteristics of the Patients.*
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−25.2 [95% CI, −36.1 to −14.3; P<0.001]; Norfolk 
QOL-DN score, −16.4 [95% CI, −27.3 to −5.4; 
P = 0.004]) (Figs. S4 and S5 in the Supplementary 
Appendix). Global longitudinal strain and other 
echocardiographic variables, however, did not 
differ significantly between the inotersen group 
and the placebo group after 15 months of inter-
vention (Table S6 in the Supplementary Appen-
dix). Further subgroup analyses according to geo-
graphic region, age, sex, and patient-reported race 
showed significant benefit in favor of inotersen 
in the mNIS+7 at week 66 (Figs. S6 and S7 in the 
Supplementary Appendix). The least-squares mean 
difference between the trial groups for body-mass 
index showed a trend in favor of inotersen to slow 
weight loss (Table S7 in the Supplementary Ap-
pendix).
Secondary and Tertiary Efficacy End Points
Results from analyses of the mNIS+7 test at the 
component and subcomponent level, as well as 
the Norfolk QOL-DN questionnaire according to 
domain, are shown in Figure S8 in the Supple-
mentary Appendix, along with the results from 
a second quality-of-life instrument, the 36-Item 
Short Form Health Survey (Table S8 in the Sup-
plementary Appendix).
Pharmacodynamics
In the inotersen group, reductions in circulating 
transthyretin reached steady-state levels by week 
13 and were sustained through the end of the 
intervention period (Fig. S9 in the Supplementary 
Appendix). From week 13 to week 65, decreases 
in serum transthyretin from baseline levels in the 
inotersen group reached a median nadir of 79.0% 
and mean nadir of 74.0%. There was no correla-
tion between the absolute or relative change from 
baseline in serum transthyretin levels and the 
change from baseline in the mNIS+7 score in pa-
tients who received inotersen (Pearson’s r, 0.11, 
and P = 0.33 for absolute change; Pearson’s r, 0.06, 
and P = 0.57 for relative change) (Fig. S10 in the 
Supplementary Appendix). These findings were 
consistent with a flat drug exposure–response 
relationship, which was expected at the single-
dose level.
Safety
There were five deaths during the trial, all in the 
inotersen group (Table 2). Four of the five deaths 
were consistent with progression or complication 
of the underlying disease (two deaths from ca-
chexia and one each from intestinal perforation 
and congestive heart failure) (Table S9 in the Sup-
plementary Appendix). One patient in the inotersen 
group had a fatal intracranial hemorrhage in as-
sociation with a platelet count of less than 10,000 
per cubic millimeter that occurred before the in-
troduction of frequent platelet monitoring.
Glomerulonephritis occurred in three patients 
(3%) in the inotersen group (Table 2). Each of these 
Figure 2. Change from Baseline in Primary End Points.
Brackets indicate the difference in the least-squares mean change from 
baseline between the inotersen group and the placebo group. Composite 
scores on the modified Neuropathy Impairment Score+7 (mNIS+7) scale 
range from −22.3 to 346.3 (the higher the score, the poorer the function), 
and total scores on the Norfolk Quality of Life–Diabetic Neuropathy (QOL-DN) 
questionnaire range from −4 to 136 (the higher the score, the poorer the 
quality of life). A decrease in score indicated an improvement on each 
scale. A 2-point change in the NIS+7 has been defined as the minimal clini-
cally meaningful change detectable.14,18 Changes in the patient-reported 
Norfolk QOL-DN score have been shown to be proportional to changes in 
the Neuropathy Impairment Score (range, 0 to 244, with a higher score in-
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three patients carried the Val30Met mutation. 
Two had shown a decline in the estimated glo-
merular filtration rate. In all three cases, the renal 
biopsy showed complex pathologic features, con-
sistent with crescentic glomerulonephritis super-
imposed on a background of amyloidosis and (in 
two cases) interstitial fibrosis. One patient was 
successfully treated with glucocorticoids and cy-
clophosphamide and regained clinically signifi-
cant renal function. Another patient did not re-
ceive immunosuppressive therapy owing to delayed 
diagnosis, and permanent hemodialysis was initi-
ated. A third patient was identified as having 
clinically significant proteinuria after the imple-
mentation of more frequent renal monitoring of 
every 2 to 3 weeks; this patient did not show a 
decline in renal function. Urinary protein excre-
tion returned to baseline levels after treatment 
with glucocorticoids.
A higher proportion of patients in the inoter-
sen group (60 of 112, 54%) had a confirmed de-
crease in the postbaseline platelet count to less 
than 140,000 per cubic millimeter than in the 
placebo group (8 of 60, 13%) (Table S10 in the 
Supplementary Appendix). Decreases in the inot-
ersen group occurred gradually over a period of 
several weeks, with an onset within the first 13 
weeks of dosing and a mean nadir between 3 to 
6 months after treatment initiation (Fig. S11 in 
the Supplementary Appendix). Thrombocytopenia 
with platelet counts of less than 25,000 per cubic 
millimeter occurred in 3 patients (3%) who re-
ceived inotersen. Platelet counts in 2 of these 
3 patients returned to baseline or near-baseline 
levels after discontinuation of the trial regimen 
and treatment with glucocorticoids. The third pa-
tient presented with an intracranial hemorrhage 
and died before treatment could be initiated. No 
cases of thrombocytopenia with platelet counts of 
less than 50,000 per cubic millimeter occurred 
after the institution of weekly platelet monitoring. 
Two patients in the inotersen group had a dose 
reduction to 150 mg weekly because of decreases 
in platelet counts. There was some evidence of an 
immune-mediated mechanism in the severe events, 
as indicated by recovery with glucocorticoid treat-
ment and the presence of antiplatelet IgG in each 
of the 3 patients. Importantly, further investiga-
tion ruled out a heparin-induced thrombocytope-
nia–type mechanism and effects on platelet pro-
duction.
Adverse events with both an incidence of at 
least 10% in either group and an incidence that 
was at least twice as high in the inotersen group 
as in the placebo group were nausea, pyrexia, 
chills, vomiting, anemia, thrombocytopenia, and 
lowered platelet counts (Table S11 in the Supple-
mentary Appendix). Some events were consistent 
with known symptoms or complications of the 
underlying disease, such as nausea, vomiting, and 
anemia. The incidence of hemorrhages was simi-
lar in the two groups.
The mean rate of injection-site reactions was 
1.1% of all injections in the inotersen group. A 
total of 68 events were reported by 36 patients. 
A total of 97% of the events were mild in severity. 
There were no severe events, and no patient dis-
continued inotersen treatment prematurely owing 
to events at the injection site. The mean percent-
age of subcutaneous injections that were admin-
istered at home was approximately 80% in both 
trial groups (Table S12 in the Supplementary 
Appendix).






no. of patients (%)
Any adverse event 60 (100) 111 (99)
Event related to trial regimen† 23 (38) 87 (78)
Any serious adverse event 13 (22) 36 (32)
Event related to trial regimen† 1 (2) 8 (7)
Glomerulonephritis 0 3 (3)‡
Thrombocytopenia 0 2 (2)
Deep-vein thrombosis 1 (2) 1 (<1)
Intracranial hemorrhage 0 1 (<1)§
Tubulointerstitial nephritis 0 1 (<1)¶
Pulmonary embolism 0 1 (<1)
Embolic stroke 0 1 (<1)
Myelopathy 0 1 (<1)
Death 0 5 (4)
*  Shown are adverse events that occurred from the time of the first dose to the 
end of the trial, including the postintervention follow-up period.
†  Shown are patients with events that were considered by the investigator to be 
related or possibly related to the trial regimen, as well as patients with miss-
ing data on the relatedness of the event to the trial regimen.
‡  The event for one patient was originally reported as acute kidney injury but 
was subsequently diagnosed by biopsy as glomerulonephritis.
§  The patient had a fatal intracranial hemorrhage that was associated with grade 4 
thrombocytopenia.
¶  The patient also had glomerulonephritis that was confirmed by biopsy.
Table 2. Summary of Adverse Events.*
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body-weight change, corrected QT interval (Frid-
ericia’s formula), concomitant medications, sui-
cidal ideation or behavior, and ERG results, were 
either similar in the two trial groups or were 
modified favorably during inotersen treatment. 
There were no clinical manifestations of vitamin A 
deficiency.
Discussion
In this international, randomized, placebo-con-
trolled trial, inotersen modified the course of 
neuropathy and improved quality of life in patients 
with hereditary transthyretin amyloidosis. Both 
primary end points, the mNIS+7 and the Norfolk 
QOL-DN score, showed significant benefits with 
inotersen treatment. These benefits were indepen-
dent of TTR mutation type, disease stage, and 
cardiomyopathy status at baseline. Subcutaneous 
injections of inotersen and placebo were adminis-
tered at home, outside prespecified clinical vis-
its. The clinical response to inotersen treatment 
was probably due to many factors in addition to 
the lowering of transthyretin levels, including the 
individual rate of disease progression, baseline 
amyloid burden, and the rate of amyloid clearance 
from tissue. Results from the NEURO-TTR trial 
are similar to those from a trial of patisiran, also 
published in this issue of the Journal, which used 
a lipid nanoparticle–encapsulated small interfer-
ing RNA to lower production of transthyretin.25
The principal safety concerns that were iden-
tified for inotersen treatment were thrombocy-
topenia (three patients had a platelet count of 
<25,000 per cubic millimeter), the occurrence of 
glomerulonephritis (three patients), and an im-
balance in deaths from any cause (five patients, 
as compared with none in the placebo group). 
We cannot be sure whether this imbalance was 
due to acceleration of the underlying disease in 
some cases, the play of chance, or some other 
cause. After the implementation of enhanced 
monitoring, no additional cases of severe thrombo-
cytopenia occurred, and a single case of glomeru-
lonephritis was identified early without loss of 
renal function. Integrated analysis of clinical data 
from patients treated systemically with antisense 
oligonucleotides from the same 2′-O-methoxy-
ethyl–modified chemical class suggests that these 
severe events may represent a drug–disease in-
teraction.26-28
Limitations of the current trial included the 
exclusion of patients with end-stage disease and 
insufficient power to measure the effects of inoter-
sen treatment on cardiomyopathy.29 In addition, 
patients who were assigned to receive inotersen 
had more advanced autonomic neuropathy and 
sensorimotor neuropathy than those assigned to 
receive placebo, and a greater proportion had car-
diomyopathy at trial entry.
In conclusion, weekly subcutaneous injections 
of inotersen provided benefit to patients with he-
reditary transthyretin amyloidosis with polyneu-
ropathy, as measured by both clinical assessments 
and quality-of-life instruments. Implementation of 
enhanced safety monitoring allowed early detec-
tion and management of thrombocytopenia and 
glomerulonephritis.
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